Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Medicus Sciences Acquisition Corp. | tm2111538d1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 1, 2021
Medicus Sciences Acquisition Corp.
(Exact name of registrant as specified in its charter)
| Cayman Islands | 001-40068 | N/A | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
152 West 57th Street, Floor 20
New York, New York 10019
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (212) 259-8400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-ninth of one redeemable warrant | MSACU | The Nasdaq Stock Market LLC | ||
| Class A ordinary shares included as part of the units | MSAC | The Nasdaq Stock Market LLC | ||
| Redeemable warrants included as part of the units | MSACW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On April 1, 2021, Medicus Sciences Acquisition Corp. (the “Company”) announced that, commencing April 5, 2021, the Company’s units will no longer trade, and that the Company’s Class A ordinary shares and warrants, which together comprise the units will commence trading separately. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “MSAC” and “MSACW,” respectively. This is a mandatory and automatic separation, and no action is required by the holders of units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are being filed herewith:
| Exhibit No. | Description | |
| 99.1 | Press Release, dated April 1, 2021. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 1, 2021
| MEDICUS SCIENCES ACQUISITION CORP. | ||
| By: | /s/ Michael Castor | |
| Name: Michael Castor | ||
| Title: Chief Executive Officer | ||